Disease · HP_0001880
Increased total eosinophil count
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Increased total eosinophil count. Diseases, record HP_0001880. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001880
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Increased total eosinophil count
- Open Targets ID
- HP_0001880
- Other names
- Eosinophilia, High blood eosinophil count, Increased eosinophil count
- Highest stage of its drugs
- Phase 2, for 4 of its 9 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEXPRAMIPEXOLE | CHEMBL249420 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIETHYLCARBAMAZINE | CHEMBL684 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FEVIPIPRANT | CHEMBL3137332 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RESLIZUMAB | CHEMBL2107884 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEPEMOKIMAB | CHEMBL4650469 | Antibody | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALBENDAZOLE | CHEMBL1483 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IVERMECTIN | CHEMBL6067487 | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| LAZUCIRNON | CHEMBL3670800 | Small molecule | Unknown | USAN | 1 | 0 | 0 | Drugs and targets |
| LAZUCIRNON HYDROCHLORIDE | CHEMBL4594296 | Small molecule | Unknown | USAN | 1 | 0 | 0 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL5 | Interleukin-5 | 2 | Interleukin-5 inhibitor | Phase 2 | https://conductscience.org/library/genes/3567 | Drugs and targets |
| PTGDR2 | Prostaglandin D2 receptor 2 | 1 | G protein-coupled receptor 44 antagonist | Phase 2 | https://conductscience.org/library/genes/11251 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03287310 | First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma | Phase 1 | 50 | 2021-03-01 | Asthma | DEPEMOKIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01111305 | Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis | Phase 2 | 31 | 2017-06-01 | Loiasis | DIETHYLCARBAMAZINE, RESLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06265870 | Specific Versus Empirical Anthelminthic Treatment in Eosinophilia | Not applicable | 700 | Eosinophilia | ALBENDAZOLE, IVERMECTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01545726 | Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma | Phase 2 | 61 | Asthma | FEVIPIPRANT | Its record names the disease | ClinicalTrials.gov | |
| NCT02101138 | Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome | Phase 2 | 15 | Hypereosinophilic Syndrome | DEXPRAMIPEXOLE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Reslizumab + DEC vs Placebo + DEC: deaths from any cause | 0 of 4 | 0 of 4 | 8 | NCT01111305 | Trial comparisons |
| Reslizumab + DEC vs Placebo + DEC: serious adverse events | 0 of 4 | 0 of 4 | 8 | NCT01111305 | Trial comparisons |
Papers from its trials21
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001880
GET https://conductscience.org/api/diseases/v1/HP_0001880/papers?page=2